|
|
|
|
Evidence for the effectiveness of these drugs in multiple sclerosis is problematic because there are few good qualities for each drug. Trials often have methodological limitations and use different treatment regimes, patient groups, and out come measures. Well conducted trials using outcome measures with clinical significance for groups of patients with different types of multiple sclerosis and long term follow up are needed if the evidence base of treatment for the disease is to be improve d. |
|